Thyrocare Technologies Ltd

Q1 FY26Healthcare Services

Thyrocare Technologies Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹566

Market cap₹9.5K Cr

P/E52.8

Updated23 Aug 2026

Read4 min read

The short version

Consistent mid-teens growth guidance in revenue and volume for the year, with strong Q1 performance indicating promising momentum. Thyrocare expects to maintain EBITDA margins around 30%, with any excess reinvested into the business to drive growth.

From Thyrocare Technologies Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Consistent mid-teens growth guidance in revenue and volume for the year, with strong Q1 performance indicating promising momentum.
Expectation to add 1,200 to 1,500 new franchises during the year, maintaining approximately 100 franchise additions per month.
Growth driven by both organic expansion (21% in Q1) and inorganic growth via acquisitions (around 2%).
Strong focus on increasing franchisee revenue, which grew 20% YoY in Q1 FY26.
Partnership revenue grew 36% YoY in Q1, with ongoing expansion in health check segments and onboarding new clients.
Expansion of franchise footprint pan-India, with secular growth spread across regions, avoiding concentration in any single geography.

2 more points management made on revenue & sales performance

Profitability & Margins

Thyrocare expects to maintain EBITDA margins around 30%, with any excess reinvested into the business to drive growth.
Operating leverage is present, but the company is cautious due to ongoing reinvestment plans and acquisition activities.
The company continues to actively seek acquisitions to accelerate expansion and growth.
Revenue guidance remains mid-teens growth in both volume and value, with caution on early-year optimism.
Franchisee network expansion is targeted at 1,200-1,500 net additions annually, supporting revenue growth.
Profit after tax (PAT) grew 62% YoY in Q1 FY26; EBITDA margin was strong at 33%.
Growth is driven by factors like franchise additions, menu expansion, and partnership businesses.

2 more points management made on profitability & margins

See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Investment of approximately ₹3 to ₹4 lakh is required to set up a franchise collection center, including infrastructure like boards, mirrors, and sample collection area.
Franchise deposit is minimal and mostly provided by about 10% of franchisees with boards; the deposit is refunded as wallet balance used for business.
Thyrocare is moving towards a CAPEX model for equipment procurement in pathology labs, capitalizing machines on their books instead of reagent rental (RR) model.
Recent acquisitions (Polo Lab, Vimta Clinical Diagnostics, Think Health) are fully integrated, supporting strategic expansion in North and South India.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
The company emphasizes being debt-free and prefers financing equipment through CAPEX model rather than reagent rental or external financing.
No indication of new equity issuance or raising capital through stock offerings was discussed.

2 more points management made on fundraising & capital structure

See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript and pages do not contain any mention or discussion about the current or expected order book or pending orders for Thyrocare Technologies Limited. The Q&A and management discussion focus primarily on: - Revenue growth and business segments (franchisee and partnership revenue). - Test menu expansion and new specialized tests. - Acquisition integrations (Polo Lab, Vimta, Think Health). - Supply chain and reagent sourcing details.

2 more points management made on order book & pipeline

Thyrocare Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹224 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Thyrocare Technologies Ltd's management said in earlier quarters

Others in Healthcare Services this season

Aster DM Quality (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
Syngene International Ltd (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
Yatharth Hospit. (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Thyrocare Technologies Ltd Q1 FY26 results?

What is Thyrocare Technologies Ltd share price analysis?

Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.

Is Thyrocare Technologies Ltd planning capital expenditure?

Investment of approximately ₹3 to ₹4 lakh is required to set up a franchise collection center, including infrastructure like boards, mirrors, and sample collection area.

Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.